Skip to main content
Top
Published in: Trials 1/2018

Open Access 01-12-2018 | Research

Outcomes, Interventions and Funding in Randomised Research Published in High-Impact Journals

Authors: Patrick Grey, Andrew Grey, Mark J. Bolland

Published in: Trials | Issue 1/2018

Login to get access

Abstract

Background

Randomised clinical trials are pivotal in guiding clinical practice. Trials with surrogate outcomes and industry sponsorship might be less reliable than those with hard outcomes and independent sponsorship. The types of interventions evaluated in randomised clinical trials might not reflect the diversity of those employed in clinical practice.

Methods

We assessed the types of primary outcome, types of intervention and sponsorship of 360 randomised clinical trials evaluating 416 interventions, published in seven major general medical journals and 10 speciality medical journals in five clinical disciplines.

Results

Primary outcomes were surrogate in 223/360 (62%) trials. Neither type of journal nor source of sponsorship was associated with type of primary outcome. Among the interventions evaluated, 233/416 (56%) were drugs, 17/416 (4%) devices and 49/416 (12%) procedures. The majority of trials were non-industry funded (220/360, 61%). Trials of drug interventions and those with industry sponsorship were more common in specialty than general journals (68% vs 48% and 55% vs 25%, respectively). Industry sponsorship was not associated with results for the primary outcome but was strongly associated with trials of drugs and devices.
Within the groups of both general and speciality journals, there were wide ranges in the prevalence of industry funding (7–63% and 37–70%, respectively), but in all cases the prevalence of hard primary outcomes was <40%.

Conclusions

Most randomised clinical trials published in influential journals reported surrogate primary outcomes and assessed drug interventions. Trials that evaluated devices and procedures were infrequently published, despite the prominence of each type of intervention in clinical practice. Industry funding was more common for trials published in specialty than general journals but was not associated with more positive results for primary outcomes or with a greater preponderance of surrogate outcomes.
Literature
1.
go back to reference Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet. 2001;357(9253):373–80.CrossRef Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet. 2001;357(9253):373–80.CrossRef
2.
go back to reference Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med. 2013;173(8):611–2.CrossRef Svensson S, Menkes DB, Lexchin J. Surrogate outcomes in clinical trials: a cautionary tale. JAMA Intern Med. 2013;173(8):611–2.CrossRef
3.
go back to reference Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. BMJ. 2011;343:d7995.CrossRef Yudkin JS, Lipska KJ, Montori VM. The idolatry of the surrogate. BMJ. 2011;343:d7995.CrossRef
4.
go back to reference Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175(12):1992–4.CrossRef Kim C, Prasad V. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med. 2015;175(12):1992–4.CrossRef
5.
go back to reference Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med. 2013;173(7):580–1.CrossRef Bero L. Industry sponsorship and research outcome: a Cochrane review. JAMA Intern Med. 2013;173(7):580–1.CrossRef
6.
go back to reference Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–70.CrossRef Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003;326(7400):1167–70.CrossRef
7.
go back to reference Stamatakis E, Weiler R, Ioannidis JPA. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. Eur J Clin Investig. 2013;43(5):469–75.CrossRef Stamatakis E, Weiler R, Ioannidis JPA. Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. Eur J Clin Investig. 2013;43(5):469–75.CrossRef
8.
go back to reference Lundh A, Barbateskovic M, Hróbjartsson A, Gøtzsche PC. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. PLoS Med. 2010;7(10):e1000354.CrossRef Lundh A, Barbateskovic M, Hróbjartsson A, Gøtzsche PC. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. PLoS Med. 2010;7(10):e1000354.CrossRef
9.
go back to reference Nieuwenhuijse MJ, Nelissen RG, Schoones JW, Sedrakyan A. Appraisal of evidence base for introduction of new implants in hip and knee replacement: a systematic review of five widely used device technologies. BMJ. 2014;349:g5133.CrossRef Nieuwenhuijse MJ, Nelissen RG, Schoones JW, Sedrakyan A. Appraisal of evidence base for introduction of new implants in hip and knee replacement: a systematic review of five widely used device technologies. BMJ. 2014;349:g5133.CrossRef
10.
go back to reference Ross JS. High-risk medical devices: Why do we not better understand effectiveness and safety? JAMA Intern Med. 2015;175(6):939–40.CrossRef Ross JS. High-risk medical devices: Why do we not better understand effectiveness and safety? JAMA Intern Med. 2015;175(6):939–40.CrossRef
11.
go back to reference Prasad V, Vandross A, Toomey C, Cheung M, Rho J, Quinn S, et al. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc. 2013;88(8):790–8.CrossRef Prasad V, Vandross A, Toomey C, Cheung M, Rho J, Quinn S, et al. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc. 2013;88(8):790–8.CrossRef
12.
go back to reference McCulloch P. The EU’s system for regulating medical devices. BMJ. 2012;345:e7126.CrossRef McCulloch P. The EU’s system for regulating medical devices. BMJ. 2012;345:e7126.CrossRef
14.
go back to reference Roper N, Zhang N, Korenstein D. Industry collaboration and randomized clinical trial design and outcomes. JAMA Intern Med. 2014;174(10):1695–6.CrossRef Roper N, Zhang N, Korenstein D. Industry collaboration and randomized clinical trial design and outcomes. JAMA Intern Med. 2014;174(10):1695–6.CrossRef
16.
go back to reference Prasad V, Rho J, Cifu A. The inferior vena cava filter: how could a medical device be so well accepted without any evidence of efficacy? JAMA Intern Med. 2013;173(7):493–5.CrossRef Prasad V, Rho J, Cifu A. The inferior vena cava filter: how could a medical device be so well accepted without any evidence of efficacy? JAMA Intern Med. 2013;173(7):493–5.CrossRef
17.
go back to reference Zuckerman DM, Brown P, Nissen SE. Medical device recalls and the FDA approval process. Arch Intern Med. 2011;171(11):1006–11.PubMed Zuckerman DM, Brown P, Nissen SE. Medical device recalls and the FDA approval process. Arch Intern Med. 2011;171(11):1006–11.PubMed
18.
go back to reference Wartolowska K, Judge A, Hopewell S, Collins GS, Dean BJF, Rombach I, et al. Use of placebo controls in the evaluation of surgery: systematic review. BMJ. 2014;348:g3253.CrossRef Wartolowska K, Judge A, Hopewell S, Collins GS, Dean BJF, Rombach I, et al. Use of placebo controls in the evaluation of surgery: systematic review. BMJ. 2014;348:g3253.CrossRef
19.
go back to reference la Cour JL, Brok J, Gotzsche PC. Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study. BMJ. 2010;341:c3653.CrossRef la Cour JL, Brok J, Gotzsche PC. Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study. BMJ. 2010;341:c3653.CrossRef
Metadata
Title
Outcomes, Interventions and Funding in Randomised Research Published in High-Impact Journals
Authors
Patrick Grey
Andrew Grey
Mark J. Bolland
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Trials / Issue 1/2018
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-018-2978-8

Other articles of this Issue 1/2018

Trials 1/2018 Go to the issue